Added to YB: 2026-09-17
Pitch date: 2026-09-15
MDWD [neutral]
MediWound Ltd.
Author Info
No bio for this author
Company Info
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally.
Market Cap
$179.2M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.10
P/E
-6.18
EV/Sales
12.85
Sector
Pharmaceuticals
Category
growth
Biotech Conference Coverage: Week 2, Day 1 — Part 2: MediWound Ltd.
MDWD (quick overview): MediWound’s approved NexoBrid burn treatment provides commercial and regulatory proof of concept for its bromelain-based enzymatic-debridement platform; the chronic-wound readout is company-defining. Around 80 U.S. burn centers have ordered NexoBrid, while management cites 14 successful trials out of 14. The key constraints are gradual protocol-driven adoption and manufacturing capacity, with European approval of the expanded facility expected around mid-2027 and FDA inspection later.
Read full article (1 min)